Wendy Perrow, MBA, Chief Executive Officer,

Wendy Perrow is the CEO of AsclepiX Therapeutics and is responsible for managing the Company’s business, clinical, financial, licensing, and corporate development efforts.  Ms. Perrow previously served as CEO of Alba Therapeutics.  Under her leadership, Alba Therapeutics completed a licensing agreement with Innovate Biopharmaceuticals, Inc. on February 29, 2016.  The company conducted seven clinical trials in patients with Celiac Disease, completed the largest Phase IIb clinical trial in patients with celiac disease and validated the 1st Celiac Disease Patient Reported Outcome (CeD PRO) with the lead compound Larazotide Acetate.  Prior to joining AsclepiX, Ms. Perrow held senior executive positions with private and public pharmaceutical companies.  From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with Rare and Orphan Diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global markets including Europe, Asia, and Latin America and U.S. At Merck, she held positions in marketing, marketing promotion, international business research analysis, training, and sales. A skilled marketer and business leader, she has led U.S. and Global launches/initiatives for Zocor®, Vasotec®, Varivax®, Cozaar® and Hyzaar®.  Ms. Perrow began her career in a division of Johnson & Johnson.  Ms. Perrow received her MBA in International finance and marketing from The Fuqua School of Business at Duke University and received her bachelor’s degree from Eastern Illinois University.  She is a member of the Duke Fuqua School of Business Alumni Board, Maryland Life Sciences Advisory Board, Maryland TEDCO Review Board, Healthcare Business Women’s Association, and Women in Bio.

 

GREEN PortraitJordan J. Green, Ph.D., Co-Founder and Chief Technology Officer,

is also an Associate Professor of Biomedical Engineering, Ophthalmology, Oncology, Neurosurgery, and Materials Science & Engineering at the Johns Hopkins University School of Medicine. He is an executive committee member of the Institute for NanoBioTechnology, co-founder of the Translational Tissue Engineering Center at JHU, and part of the Wilmer Eye Institute and the Sydney Kimmel Comprehensive Cancer.  He has strong expertise in nanotechnology, biomaterials, and drug delivery that includes doctoral and postdoctoral training at MIT with Institute Professor Robert Langer and consulting/collaborative work with biotechnology companies.  He has published over 70 scientific papers in these areas as well as 12 issued or pending patents.  He has received numerous honors including the Maryland Outstanding Young Engineer Award, the Biomedical Engineering Society Rita Schaffer Award, the American Institute of Chemical Engineers Nanoscale Science & Engineering Forum Young Investigator Award, the American Society for Gene & Cell Therapy Outstanding New Investigator Award, the Allan P. Colburn Award for Excellence in Publications by the American Institute of Chemical Engineers, the Presidential Early Career Award for Scientists and Engineers, and was named by Baltimore Business Journal as one of the “40 Under 40” and by Popular Science as one of the “Brilliant Ten.”  Dr. Green has given more than 65 invited national/international talks and has served on national grant panels for the National Institutes of Health, the National Science Foundation, and the Department of Defense.  His work on angiogenesis and on drug delivery has been supported by grants from the National Institutes of Health, the Maryland Technology Development Corporation, the Coulter Foundation, and the Edward N. and Della L. Thome Memorial Foundation, Award in Age-Related Macular Degeneration Research.

 

POPEL Aleksander

Aleksander S. Popel, Ph.D., Co-Founder and Chief Scientific Officer,

is also a Professor of Biomedical Engineering at the Johns Hopkins University School of Medicine. He holds joint appointments as Professor of Oncology in the School of Medicine, and Professor of Chemical & Biomolecular Engineering in the Johns Hopkins Whiting School of Engineering. He is a member of the Institute for Nanobiotechnology, In Vivo Cellular Molecular Imaging Center, and the Sydney Kimmel Comprehensive Cancer Center. His areas of expertise are angiogenesis and microcirculation, systems biology, computational medicine & biology. He published over 300 scientific papers in these areas. He served as a Visiting Professor at MIT and Harvard University. He is the recipient of the Eugene M. Landis Award from the Microcirculatory Society. He delivered keynote addresses for The Virtual Physiological Human (VPH) European Union Physiome Project and Next-Generation Integrated Simulation of Living Matter Project in Japan; he was C. Forbes Dewey Distinguished Lecturer in Biological Engineering at the Massachusetts Institute of Technology, delivered A.C. Suhren Lecture at Tulane University, Robert M. and Mary Haythornthwaite Distinguished Lecturer at Temple University, and Kawasaki Medical Society Lecturer in Japan. He is a Fellow of the American Institute of Medical and Biological Engineering, American Heart Association, American Physiological Society, and American Society of Mechanical Engineers, and an Inaugural Fellow of the Biomedical Engineering Society. He has been a member of editorial boards of biological and biomedical engineering journals. He served in an advisory role to biotech and pharmaceutical companies. He regularly serves on grant review boards and advisory panels at the National Institutes of Health, National Science Foundation, and other US and international funding agencies. His work on angiogenesis at the Johns Hopkins University has been supported by grants from the National Institutes of Health, the Safeway Breast Cancer Foundation, the Maryland Technology Development Corporation, the Coulter Foundation Translational Partnership, and the Edward N. and Della L. Thome Memorial Foundation, Award in Age-Related Macular Degeneration Research.

 

Niranjan-

Niranjan B. Pandey, Ph.D., Senior Director of R&D

Following his undergraduate degree in biochemistry from Brandeis University, Dr. Pandey received his Ph.D. in molecular biophysics from Florida State University, and completed postdoctoral fellowships at Harvard and MIT in genetics and immunology. He spent 7 years as a senior scientist in the Cancer Therapeutics Team at Johnson & Johnson developing drugs for metastatic breast cancer. Dr. Pandey continued in the biopharmaceutical sector by joining Alba Therapeutics as the Director of Biology, a position he held for 3 years. At Alba Therapeutics he was responsible for characterizing the mechanism of action of the lead clinical candidate for celiac disease. Currently he is leading the effort to develop drugs for diseases characterized by excessive angiogenesis such as age-related macular degeneration and diabetic macular edema.